Drugs / Peptide T
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00000393 | Jan 1988 → Jan 1990 | HIV infectious disease, cognitive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 1 | NCT00000391 | Jan 1988 → Jan 1990 | HIV infectious disease | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00002083 | — | HIV infectious disease, peripheral neuropathy | Advanced Peptides | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00000392 Comparator | Jan 1990 → Aug 1996 | HIV infectious disease, cognitive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptide T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002083 ↗ |
| Known as | D-Ala-1-peptide-T-amide | “To study the safety, toxicology, and activity of Peptide T (D-Ala-1-peptide-T-amide) in humans and to find out more about the ability of peptide T to prevent, halt, and/or...” NCT00000393 ↗1“intranasal peptide T (D-Ala-1-peptide-T-amide)” NCT00000391 ↗ |
| Action | Inhibit | “Peptide T also binds to this site, and thus by competing for that site, can block the binding of the virus to its receptor.” NCT00000391 ↗ |
| Modality | Peptide | “intranasal peptide T (D-Ala-1-peptide-T-amide)” NCT00000391 ↗ |
| Route | Intranasal | “intranasal peptide T” NCT00000391 ↗ |
| Target | CD4 | “HIV binds to the receptor CD4 site. Peptide T also binds to this site” NCT00000391 ↗ |